Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Isabella Capodanno

Brentuximab Vedotin Followed by ABVD +/− Radiotherapy in Patients With Previously Untreated Hodgkin Lymphoma: Final Results of a Pilot Phase II Study

Haematologica

Hematology

2015

English

Chronic Myeloid Leukaemia With Extreme Thrombocytosis at Presentation: Incidence, Clinical Findings and Outcome

British Journal of Haematology

Hematology

2017

English

Related publications

Phase I/Ii Study of Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Patients Treated by Chemotherapy (Ice) in Second Line Before Autologous Transplantation.

Hematological Oncology

English

Phase 1b Keynote-013 Study of Pembrolizumab in Patients With Classic Hodgkin Lymphoma After Brentuximab Vedotin Failure: Results of >4 Years of Follow-Up

Hematological Oncology

English

First Salvage Treatment With Bendamustine and Brentuximab Vedotin in Hodgkin Lymphoma: A Phase 2 Study of Fil Onlus

Hematological Oncology

English

Pulmonary Toxicity in Paediatric Patients With Relapsed or Refractory Hodgkin Lymphoma Receiving Brentuximab Vedotin

British Journal of Haematology

Hematology

2018

English

Brentuximab Vedotin Salvage Followed by Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in High Risk Relapsed Refractory Hodgkin Lymphoma

Hematological Oncology

English

Dose Dense Abvd (Dd-Abvd) as First Line Therapy in Early-Stage Unfavorable Hodgkin Lymphoma (Hd): Results of a Phase Ii, Prospective Study by Fondazione Italiana Linfomi

Hematological Oncology

English

Brentuximab Vedotin in Patients With Relapsed HIV-Related Lymphoma

Journal of the National Comprehensive Cancer Network : JNCCN

Medicine

Oncology

2014

English

Brentuximab Vedotin for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey

English

A Phase 1/2 Study of Brentuximab Vedotin in Pediatric Patients With Relapsed/Refractory (R/R) Systemic Anaplastic Large-Cell Lymphoma (Salcl) or R/R Hodgkin Lymphoma (Hl)

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Isabella Capodanno

Brentuximab Vedotin Followed by ABVD +/− Radiotherapy in Patients With Previously Untreated Hodgkin Lymphoma: Final Results of a Pilot Phase II Study

Chronic Myeloid Leukaemia With Extreme Thrombocytosis at Presentation: Incidence, Clinical Findings and Outcome

Related publications

Phase I/Ii Study of Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Patients Treated by Chemotherapy (Ice) in Second Line Before Autologous Transplantation.

Phase 1b Keynote-013 Study of Pembrolizumab in Patients With Classic Hodgkin Lymphoma After Brentuximab Vedotin Failure: Results of >4 Years of Follow-Up

First Salvage Treatment With Bendamustine and Brentuximab Vedotin in Hodgkin Lymphoma: A Phase 2 Study of Fil Onlus

Pulmonary Toxicity in Paediatric Patients With Relapsed or Refractory Hodgkin Lymphoma Receiving Brentuximab Vedotin

Brentuximab Vedotin Salvage Followed by Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in High Risk Relapsed Refractory Hodgkin Lymphoma

Dose Dense Abvd (Dd-Abvd) as First Line Therapy in Early-Stage Unfavorable Hodgkin Lymphoma (Hd): Results of a Phase Ii, Prospective Study by Fondazione Italiana Linfomi

Brentuximab Vedotin in Patients With Relapsed HIV-Related Lymphoma

Brentuximab Vedotin for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey

A Phase 1/2 Study of Brentuximab Vedotin in Pediatric Patients With Relapsed/Refractory (R/R) Systemic Anaplastic Large-Cell Lymphoma (Salcl) or R/R Hodgkin Lymphoma (Hl)